Storia in 2 fonti

Ethyreal lands $101M to treat both Graves' and thyroid eye disease

Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye disease, with a clinic entry planned by end of 2026.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Ethyreal lands $101M to treat both Graves' and thyroid eye disease

Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye disease, with a clinic entry planned by end of 2026.

originale

biopharmadive.com1 mese fa

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

Leggi questa versione → originale

Timeline cronologica

mercoledì 10 giugno 2026·biopharmadive.com
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
mercoledì 10 giugno 2026·endpoints.news
Ethyreal lands $101M to treat both Graves' and thyroid eye disease
Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye disease, with a clinic entry planned by end of 2026.